Importance in Type 1 Diabetes Patients of an Optimized Control of Post-Prandial Glycaemia on Oxidant Stress Prevention
NCT00934336 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50
Last updated 2015-08-07
Summary
The aim of this study is to determine whether postprandial hyperglycaemia plays an important role in oxidative stress phenomena and influences their harmful effects on the arterial wall.
25 type 1 diabetic patients practicing FIT and with an HbA1c value of 8 percent or less at the beginning of the study will be recruited. The 25 control subjects will be recruited after the patients, so that they can be paired by age and sex.
Patients will be randomized via an alternative cross over study design for 2 periods of 3 months, i.e. preprandial or postprandial injection of an ultra fast acting analog. During the 6 months of the study, slow acting analog doses will be adjusted on the basis of basal glycaemia values. The fast acting analog doses will be adjusted on the basis of an optimized algorithm available on each patient's PDA phone electronic diary.
Blood and urine samples will be collected at M0, M3 and M6 to evaluate the stress oxidant grade and its consequence on atherogenesis:
Oxidative Stress evaluation: plasma parameters (lipid peroxide derivatives, semicarbazide sensitive oxidase amine activity), erythrocyte and leukocyte cell parameters (reduced and oxidised glutathion, dismutase superoxide activity (SOD) Cu and Mn dependent, glutathion peroxidase, and catalase), urinary parameters (isoprostane F2) Evaluation of consequences of oxidative stress on atherogenesis processes: inflammatory parameters (CRP, TNFa, IL 6), adhesion molecules (VCAM 1, ICAM 1, P selectine), adipokines (leptine, resistine, adiponectine), coagulation factors (PAI 1), platelet and endothelial microparticles, The pre and postprandial glycaemic stability of each patient will be monitored using PDA phone systems, and HbA1c will be measured at M0, M3 and M6.
Expected results and outcomes:
It is important to know if, in patients with comparable glycaemic stability, these two insulin treatment regimens are associated with significant differences in oxidative stress and anti oxidant defenses.
These results may help us to define a postprandial insulin treatment regimen (which is more flexible as regards meals) or a preprandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
Conditions
Interventions
- OTHER
-
Therapeutic and preventive strategies
These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
- OTHER
-
Therapeutic and preventive strategies
These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
Sponsors & Collaborators
-
Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
lead OTHER
Principal Investigators
-
FEVE Bruno, MD PH · Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète
-
CHARPENTIER Guillaume, PH · CH Sud Francilien
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- CROSSOVER
Eligibility
- Min Age
- 18 Years
- Max Age
- 50 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2008-11-30
- Primary Completion
- 2011-04-30
- Completion
- 2011-04-30
Countries
- France
Study Locations
More Related Trials
-
Insulin Deprivation on Brain Structure and Function in Humans With Type 1 Diabetes
NCT03392441 ·Status: COMPLETED ·Phase: NA
-
Postprandial Gut Hormone Responses in Patients With Type 1 Diabetes Mellitus
NCT04430946 ·Status: UNKNOWN ·Phase: NA
-
Sleep Apnea in Type 1 Diabetes
NCT01935765 ·Status: COMPLETED ·Phase: NA
-
Effects of Prebiotics on GLP-1 in Type 2 Diabetes
NCT02569684 ·Status: COMPLETED ·Phase: NA
-
Postprandial Blood Glucose Control and Gastric Emptying in Type 1 Diabetes: Pathogenetic Factors and Therapeutic Options
NCT02365740 ·Status: UNKNOWN ·Phase: NA
-
Eating Disturbances in Patients With Type 1 Diabetes Initiating Insulin Therapy
NCT07151924 ·Status: ACTIVE_NOT_RECRUITING
-
The Importance of Meal Composition on Preventing Exercise-induced Hypoglycemia in People With Type 1 Diabetes.
NCT04472962 ·Status: COMPLETED ·Phase: NA
-
Glucagon and Advanced HCL System to Prevent Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
NCT05379686 ·Status: COMPLETED ·Phase: NA
-
Incretin Hormones in Type-1 Diabetes Mellitus Glycemic Response in Type-1 Diabetes Mellitus
NCT00832741 ·Status: COMPLETED
-
Glucose-dependent Insulinotropic Polypeptide as a Safeguard Against Hypoglycemia in Patients With Type 1 Diabetes
NCT03556098 ·Status: COMPLETED ·Phase: NA
-
Pathophysiological Implications of the Incretin Hormones in Maturity Onset of Diabetes of the Young (MODY)
NCT01342939 ·Status: COMPLETED
-
Cardiovascular Effects of Rapidly Declining Plasma Glucose in Patients With Type 1 Diabetes
NCT04800536 ·Status: COMPLETED ·Phase: NA
-
Very Low Carbohydrate Diets and Glucagon Response in T1DM
NCT04200391 ·Status: RECRUITING ·Phase: NA
-
Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans
NCT06333496 ·Status: COMPLETED ·Phase: NA
-
Nutritional Management of the Patient With Type 2 Diabetes at Nutritional Risk or With Malnutrition in Clinical Practice
NCT07252765 ·Status: RECRUITING
-
Incretin Hormones in Type 1 Diabetes Mellitus;Effect of Metformin Treatment
NCT04177303 ·Status: UNKNOWN ·Phase: PHASE3
-
Endothelial and Metabolic Effects of Glucagon-like Peptide-1 (GLP-1) in Coronary Circulation in Patients With Type 2 Diabetes Mellitus
NCT00923962 ·Status: COMPLETED ·Phase: NA
-
Prevalence of Overweight and Obesity in Adult Patients Suffering From Type 1 Diabetes
NCT05713448 ·Status: RECRUITING
-
Safety Study of Repeated Doses of Glucagon on Animal Starch in the Liver
NCT01986231 ·Status: COMPLETED ·Phase: NA
-
Effect of Metformin in Patients With Type-1 Diabetes With Inadequate Glycaemic Control by Insulin and Diet
NCT00118937 ·Status: COMPLETED ·Phase: PHASE4
-
Low-dose Dasiglucagon for Prevention of Insulin-Induced Hypoglycemia in People With Type 1 Diabetes
NCT04449692 ·Status: COMPLETED ·Phase: PHASE2
-
Near Normalisation of BG Improves the Potentiating Effect of GLP-1
NCT00612625 ·Status: COMPLETED ·Phase: NA
-
Impact of Dietary Fat and Menstrual Cycle Phases in Type 1 Diabetes
NCT07278063 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Incretin Physiology Associated With Steroid Hormone Treatment
NCT00713440 ·Status: COMPLETED ·Phase: NA
-
Effects of a Small Protein and Lipid Preload on Glucose Tolerance in Subjects With Impaired Glucose Homeostasis
NCT02342834 ·Status: COMPLETED ·Phase: NA